Glioma - Pipeline Insight, 2024

Glioma - Pipeline Insight, 2024

DelveInsight’s, “Glioma - Pipeline Insight, 2024” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Glioma: Understanding

Glioma: Overview

Glioma is the most common form of central nervous system (CNS) neoplasm that originates from glial cells. In the United States, there are six cases of gliomas diagnosed per 100,000 people every year. Gliomas are very diffusely infiltrative tumors that affect the surrounding brain tissue. Glioblastoma is the most malignant type while pilocytic astrocytomas are the least malignant brain tumors. In the past, these diffuse gliomas were classified into different subtypes and grades based on histopathologies such as a diffuse astrocytoma, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. Recently, gliomas were classified based on molecular and genetic markers. These advances have more specific prognostic and therapeutic benefits for patients with gliomas. In addition to molecular and genetic markers, gliomas are classified in grade I to IV based on the degree of proliferation indicated by the mitotic index and the presence or absence of necrosis. Gliomas are tumors derived from glial cells in the brain and nervous system. There are three major types of gliomas: astrocytomas (originating from astrocytes), oligodendrogliomas (from oligodendrocytes), and ependymomas (from ependymal cells). Gliomas are further classified into low-grade (I and II) and high-grade (III and IV) tumors based on cell morphology, mitotic activities, and molecular markers. The World Health Organization (WHO) grading system employs molecular markers to distinguish gliomas with significant prognostic and therapeutic implications. Astrocytomas can be either encapsulated or infiltrative, while oligodendrogliomas are less infiltrating than astrocytomas. Ependymomas are common in pediatric populations. High-grade gliomas, including glioblastomas, are the most aggressive forms of glioma and are life-threatening.

Headaches are the most common initial presenting symptom of patients with glioma. The pathophysiology of headaches is theorized to be the result of tumor growth that places a mass effect on surrounding tissue. The mass effect, in turn, leads to pressure in the microvasculature and leads to edema. Depending on the location of the tumor in the brain, the mass effect leads to signs of a brain tumor. For example, frontal lobe tumors can present with behavioral changes while dominant temporal lobe tumors can present with receptive speech problems. Other symptoms related to mass effects include nausea, vomiting, and change in vision, Seizures are the second most common symptom of presentation. The pathophysiology of seizures is attributed to tumor irritation to the cerebral cortex that leads to focal or generalized seizures. Other presenting symptoms of gliomas are tingling sensations, weakness, difficulty ambulation, and in rare cases, patients can present in a comatose state due to hemorrhage within the tumor which leads to an acute herniation syndrome.

Glioma treatment typically involves a multidisciplinary approach that includes surgery, radiation therapy, and chemotherapy Surgery is usually the first treatment option and involves removing as much of the tumor as possible. Radiation therapy and chemotherapy may be used after surgery to kill remaining tumor cells. In some cases, targeted therapy or immunotherapy may also be used. The specific treatment plan depends on the type, size, and location of the glioma, as well as the patient's health and preferences. If the glioma cannot be completely removed, treatments may focus on controlling symptoms and improving quality of life. Rehabilitation and supportive care, such as physical therapy and occupational therapy, may also be necessary to help patients regain lost motor skills or muscle strength. Complementary treatments, such as acupuncture, hypnosis, and music therapy, may also be helpful in managing symptoms.

“Glioma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Glioma pipeline landscape is provided which includes the disease overview and Glioma treatment guidelines. The assessment part of the report embraces, in depth Glioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Glioma R&D. The therapies under development are focused on novel approaches to treat/improve Glioma.

Glioma Emerging Drugs Chapters

This segment of the Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glioma Emerging Drugs

ONC 201: Chimerix

ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation. Recurrent glioma is a form of brain cancer with a particularly poor prognosis having a median overall survival of approximately eight months. Recurrent pediatric patients, with cancer that carries the H3 K27M mutation, have an even worse prognosis with median overall survival of approximately four months. Compelling responses at this stage of disease are rare and lack durability. Currently, the drug is in Phase III stage for the treatment of Glioma.

Marizomib: Bristol-Myers Squibb

Marizomib (NPI-0052) is under development for the treatment of glioblastoma. It was originally developed by Triphase and later acquired by Celgene and now Celgene was acquired by Bristol-Myers Squibb. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. Currently, the drug is in the Phase III stage of its development for the treatment of Glioblastoma.

MDNA55: Medicenna Therapeutics, Inc.

MDNA55 is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma.

CAN-3110: Candel Therapeutics

CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is designed to be conditional to the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a phase I investigator-sponsored clinical trial in patients with recurrent High Grade Glioma.

Further product details are provided in the report……..

Glioma: Therapeutic Assessment

This segment of the report provides insights about the different Glioma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Glioma

There are approx. 180+ key companies which are developing the therapies for Glioma. The companies which have their Glioma drug candidates in the most advanced stage, i.e. Phase III include Chimerix.

Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioma drugs.

Glioma Report Insights

• Glioma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glioma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Glioma drugs?
• How many Glioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CellabMED
• Oblato
• BioMed Valley Discoveries
• PharmAbcine
• Day One Biopharmaceuticals
• I-Mab Biopharma
• Chimerix
• Medicenna Therapeutics
• Daiichi Sankyo
• Eli Lilly and Company
• Candel Therapeutics
• AstraZeneca
• Aveta Biomics
• Angiochem
• Arog Pharmaceuticals
• Boehringer Ingelheim
• BioMimetix
• Bexion Pharmaceuticals
• CANbridge Life Sciences
• Crimson Biopharma
• Epitopoietic Research Corporation
• Stemgen

Key Products

• YYB-103
• OKN-007
• Ulixertinib
• TTAC-0001
• Tovorafenib
• TJ107
• ONC201
• MDNA55
• DS-1001b
• Abemaciclib
• CAN-2409
• AZD 1390
• Amax 126
• ANG1005
• Crenolanib
• BI 764532
• BMX-001
• BXQ-350
• CAN008
• CM93
• ERC1671
• hrBMP4